Anti-CD40 Ab has a variety of roles—it targets CD40+ tumor blood vessels such that they permit T cell traffic [24]; CD40+ B cells in tumors, spleen, and lymph nodes (LNs) such that they secrete increased levels of autoantibodies directed against antigen expressed on tumor cells [25]; and CD40+ DCs such that they upregulate costimulatory markers and release IL-12 to activate CD8+ T cells [88] and stimulate a specific CTL response to cross-presented tumor antigens [89, 90]. Here, CD8A is linked to neoplasm.